The Experts below are selected from a list of 3219 Experts worldwide ranked by ideXlab platform
M Robinson - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Lansoprazole in the treatment of erosive reflux esophagitis the Lansoprazole group
The American Journal of Gastroenterology, 1996Co-Authors: Donald O Castell, M Robinson, Stephen J Sontag, Joel E Richter, Marian M HaberAbstract:Objectives : This study was designed to compare Lansoprazole 30 mg, Lansoprazole 15 mg, omeprazole 20 mg, and placebo in the treatment of erosive reflux esophagitis. Methods : In a double-blind, multicenter study, 1284 patients with endoscopically diagnosed erosive reflux esophagitis were randomized to received Lansoprazole 30 mg (n = 422), Lansoprazole 15 mg (n = 218), omeprazole 20 mg (n = 431), or placebo (n = 213) once daily for 8 wk. At 2, 4, 6, and 8 wk, healing was evaluated endoscopically. Patients kept daily diaries of symptoms. Results : Healing rates at 2, 4, 6, and 8 wk were 65.3%, 83.3%, 89.4%, and 90.0%, respectively, for Lansoprazole 30 mg ; 56.3%, 74.6%, 80.3%, and 78.8% for Lansoprazole 15 mg ; 60.9%, 82.0%, 89.7%, and 90.7% for omeprazole 20 mg ; and 23.9%, 32.8%, 36.6%, and 40.0% for placebo (all active treatments higher than placebo, p < 0.001). Healing rates with Lansoprazole 30 mg were significantly higher than with Lansoprazole 15 mg at all time points (p < 0.05). Healing rates with omeprazole 20 mg were significantly higher than with Lansoprazole 15 mg at 4, 6, and 8 wk and were similar to those with Lansoprazole 30 mg. Based on patient diaries, Lansoprazole 30 mg produced better symptomatic relief than Lansoprazole 15 mg or omeprazole 20 mg, primarily early in the treatment course. Conclusions : Both Lansoprazole 30 mg and omeprazole 20 mg were more effective than Lansoprazole 15 mg in esophageal mucosal healing. Compared with omeprazole 20 mg, Lansoprazole 30 mg was as safe, was similarly effective with respect to esophageal healing, and provided superior symptomatic relief, primarily early in treatment. Lansoprazole 30 mg provided greater symptomatic relief than Lansoprazole 15 mg.
-
effective maintenance treatment of reflux esophagitis with low dose Lansoprazole a randomized double blind placebo controlled trial
Annals of Internal Medicine, 1996Co-Authors: M Robinson, Frank L Lanza, Dennis Avner, Marian M HaberAbstract:Objective : To compare the efficacy of two doses of Lansoprazole with that of placebo in preventing recurrence of erosive esophagitis in a 12-month period. Design : Randomized, double-blind, parallel, placebo-controlled trial. Setting : 25 U.S. medical centers. Patients : 173 patients with documented healing of erosive esophagitis after 8 weeks of acid-suppressing therapy. Intervention : Lansoprazole, 15 mg or 30 mg, or placebo once daily for as long as 12 months. Measurements : Endoscopy and symptom evaluation after 1, 2, 3, 6, 9, and 12 months of treatment. Endoscopy was also done whenever symptoms suggested erosive changes. Results : Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms. By month 1, 45% of placebo recipients remained healed compared with more than 90% of patients in either Lansoprazole group. By month 12, only 24% of placebo recipients remained healed compared with 79% of patients receiving 15 mg of Lansoprazole and 90% of patients receiving 30 mg of Lansoprazole. During the same period, 35% of placebo recipients remained asymptomatic compared with 72% of recipients of 15 mg of Lansoprazole and 67% of recipients of 30 mg of Lansoprazole. The 15-mg and 30-mg Lansoprazole doses did not differ significantly in maintaining healing and controlling symptoms. Follow-up after recurrence of erosion indicated that during the 12 months, 35% of placebo recipients and 2% of Lansoprazole recipients had three or more recurrences. Conclusion : Lansoprazole effectively maintains healing of erosive esophagitis. The 15-mg and 30-mg Lansoprazole doses did not differ significantly for use as maintenance treatment.
-
treatment of erosive reflux esophagitis resistant to h2 receptor antagonist therapy Lansoprazole a new proton pump inhibitor
Digestive Diseases and Sciences, 1995Co-Authors: M Robinson, Donald R Campbell, Stephen Sontag, Seymour M SabesinAbstract:Fifty-four patients with endoscopically documented therapy-resistant erosive reflux esophagitis were treated with Lansoprazole, a new proton pump inhibitor, for up to 12 weeks. Prior to entry, all had remained unhealed after treatment with at least two histamine2-receptor antagonists, at therapeutic doses or higher, for at least 12 weeks. Patients were randomized to receive either 30 or 60 mg Lansoprazole once daily. Endoscopy was performed and symptoms assessed at weeks 2, 4, 6, 8, and 12. Fifty-nine percent of the 50 evaluable patients were healed (ie, no evidence of erosions) after only two weeks of Lansoprazole. Cumulative endoscopic healing rates were 82% and 92% by week 4 and week 8, respectively, and the two doses were equally effective in healing. The 30- and 60-mg doses effected a decrease in the overall symptom score from 5.30 and 4.85 to 2.35 and 1.67, respectively, by the final treatment visit (P=0.001). No clinically significant adverse events or changes in laboratory parameters were observed, and no patients withdrew prematurely from the study. This study demonstrates that Lansoprazole therapy is highly effective in healing erosive reflux esophagitis resistant to therapy with histamine H2-receptor antagonists.
Marian M Haber - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and safety of Lansoprazole in the treatment of erosive reflux esophagitis the Lansoprazole group
The American Journal of Gastroenterology, 1996Co-Authors: Donald O Castell, M Robinson, Stephen J Sontag, Joel E Richter, Marian M HaberAbstract:Objectives : This study was designed to compare Lansoprazole 30 mg, Lansoprazole 15 mg, omeprazole 20 mg, and placebo in the treatment of erosive reflux esophagitis. Methods : In a double-blind, multicenter study, 1284 patients with endoscopically diagnosed erosive reflux esophagitis were randomized to received Lansoprazole 30 mg (n = 422), Lansoprazole 15 mg (n = 218), omeprazole 20 mg (n = 431), or placebo (n = 213) once daily for 8 wk. At 2, 4, 6, and 8 wk, healing was evaluated endoscopically. Patients kept daily diaries of symptoms. Results : Healing rates at 2, 4, 6, and 8 wk were 65.3%, 83.3%, 89.4%, and 90.0%, respectively, for Lansoprazole 30 mg ; 56.3%, 74.6%, 80.3%, and 78.8% for Lansoprazole 15 mg ; 60.9%, 82.0%, 89.7%, and 90.7% for omeprazole 20 mg ; and 23.9%, 32.8%, 36.6%, and 40.0% for placebo (all active treatments higher than placebo, p < 0.001). Healing rates with Lansoprazole 30 mg were significantly higher than with Lansoprazole 15 mg at all time points (p < 0.05). Healing rates with omeprazole 20 mg were significantly higher than with Lansoprazole 15 mg at 4, 6, and 8 wk and were similar to those with Lansoprazole 30 mg. Based on patient diaries, Lansoprazole 30 mg produced better symptomatic relief than Lansoprazole 15 mg or omeprazole 20 mg, primarily early in the treatment course. Conclusions : Both Lansoprazole 30 mg and omeprazole 20 mg were more effective than Lansoprazole 15 mg in esophageal mucosal healing. Compared with omeprazole 20 mg, Lansoprazole 30 mg was as safe, was similarly effective with respect to esophageal healing, and provided superior symptomatic relief, primarily early in treatment. Lansoprazole 30 mg provided greater symptomatic relief than Lansoprazole 15 mg.
-
effective maintenance treatment of reflux esophagitis with low dose Lansoprazole a randomized double blind placebo controlled trial
Annals of Internal Medicine, 1996Co-Authors: M Robinson, Frank L Lanza, Dennis Avner, Marian M HaberAbstract:Objective : To compare the efficacy of two doses of Lansoprazole with that of placebo in preventing recurrence of erosive esophagitis in a 12-month period. Design : Randomized, double-blind, parallel, placebo-controlled trial. Setting : 25 U.S. medical centers. Patients : 173 patients with documented healing of erosive esophagitis after 8 weeks of acid-suppressing therapy. Intervention : Lansoprazole, 15 mg or 30 mg, or placebo once daily for as long as 12 months. Measurements : Endoscopy and symptom evaluation after 1, 2, 3, 6, 9, and 12 months of treatment. Endoscopy was also done whenever symptoms suggested erosive changes. Results : Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms. By month 1, 45% of placebo recipients remained healed compared with more than 90% of patients in either Lansoprazole group. By month 12, only 24% of placebo recipients remained healed compared with 79% of patients receiving 15 mg of Lansoprazole and 90% of patients receiving 30 mg of Lansoprazole. During the same period, 35% of placebo recipients remained asymptomatic compared with 72% of recipients of 15 mg of Lansoprazole and 67% of recipients of 30 mg of Lansoprazole. The 15-mg and 30-mg Lansoprazole doses did not differ significantly in maintaining healing and controlling symptoms. Follow-up after recurrence of erosion indicated that during the 12 months, 35% of placebo recipients and 2% of Lansoprazole recipients had three or more recurrences. Conclusion : Lansoprazole effectively maintains healing of erosive esophagitis. The 15-mg and 30-mg Lansoprazole doses did not differ significantly for use as maintenance treatment.
Seymour M Sabesin - One of the best experts on this subject based on the ideXlab platform.
-
Lansoprazole heals erosive reflux esophagitis resistant to histamine h2 receptor antagonist therapy
The American Journal of Gastroenterology, 1997Co-Authors: Stephen J Sontag, Donald R Campbell, Seymour M Sabesin, David G Kogut, Roy Fleischmann, Joel E Richter, Malcolm G Robinson, Miles Mcfarland, Glen A Lehman, Donald O CastellAbstract:Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether Lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or Lansoprazole 30 mg for 4 wk followed by either Lansoprazole 30 mg or Lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the Lansoprazole group compared with the ranitidine group (p < 0.001). By 8 wk, 84% of the Lansoprazole group were healed as opposed to only 32% of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0.001) and reducing the need for antacids (p < 0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the Lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of Lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80% of patients with erosive reflux esophagitis previously resistant to histamine 112-receptor antagonist therapy.
-
treatment of erosive reflux esophagitis resistant to h2 receptor antagonist therapy Lansoprazole a new proton pump inhibitor
Digestive Diseases and Sciences, 1995Co-Authors: M Robinson, Donald R Campbell, Stephen Sontag, Seymour M SabesinAbstract:Fifty-four patients with endoscopically documented therapy-resistant erosive reflux esophagitis were treated with Lansoprazole, a new proton pump inhibitor, for up to 12 weeks. Prior to entry, all had remained unhealed after treatment with at least two histamine2-receptor antagonists, at therapeutic doses or higher, for at least 12 weeks. Patients were randomized to receive either 30 or 60 mg Lansoprazole once daily. Endoscopy was performed and symptoms assessed at weeks 2, 4, 6, 8, and 12. Fifty-nine percent of the 50 evaluable patients were healed (ie, no evidence of erosions) after only two weeks of Lansoprazole. Cumulative endoscopic healing rates were 82% and 92% by week 4 and week 8, respectively, and the two doses were equally effective in healing. The 30- and 60-mg doses effected a decrease in the overall symptom score from 5.30 and 4.85 to 2.35 and 1.67, respectively, by the final treatment visit (P=0.001). No clinically significant adverse events or changes in laboratory parameters were observed, and no patients withdrew prematurely from the study. This study demonstrates that Lansoprazole therapy is highly effective in healing erosive reflux esophagitis resistant to therapy with histamine H2-receptor antagonists.
Donald O Castell - One of the best experts on this subject based on the ideXlab platform.
-
Lansoprazole heals erosive reflux esophagitis resistant to histamine h2 receptor antagonist therapy
The American Journal of Gastroenterology, 1997Co-Authors: Stephen J Sontag, Donald R Campbell, Seymour M Sabesin, David G Kogut, Roy Fleischmann, Joel E Richter, Malcolm G Robinson, Miles Mcfarland, Glen A Lehman, Donald O CastellAbstract:Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether Lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or Lansoprazole 30 mg for 4 wk followed by either Lansoprazole 30 mg or Lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the Lansoprazole group compared with the ranitidine group (p < 0.001). By 8 wk, 84% of the Lansoprazole group were healed as opposed to only 32% of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0.001) and reducing the need for antacids (p < 0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the Lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of Lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80% of patients with erosive reflux esophagitis previously resistant to histamine 112-receptor antagonist therapy.
-
efficacy and safety of Lansoprazole in the treatment of erosive reflux esophagitis the Lansoprazole group
The American Journal of Gastroenterology, 1996Co-Authors: Donald O Castell, M Robinson, Stephen J Sontag, Joel E Richter, Marian M HaberAbstract:Objectives : This study was designed to compare Lansoprazole 30 mg, Lansoprazole 15 mg, omeprazole 20 mg, and placebo in the treatment of erosive reflux esophagitis. Methods : In a double-blind, multicenter study, 1284 patients with endoscopically diagnosed erosive reflux esophagitis were randomized to received Lansoprazole 30 mg (n = 422), Lansoprazole 15 mg (n = 218), omeprazole 20 mg (n = 431), or placebo (n = 213) once daily for 8 wk. At 2, 4, 6, and 8 wk, healing was evaluated endoscopically. Patients kept daily diaries of symptoms. Results : Healing rates at 2, 4, 6, and 8 wk were 65.3%, 83.3%, 89.4%, and 90.0%, respectively, for Lansoprazole 30 mg ; 56.3%, 74.6%, 80.3%, and 78.8% for Lansoprazole 15 mg ; 60.9%, 82.0%, 89.7%, and 90.7% for omeprazole 20 mg ; and 23.9%, 32.8%, 36.6%, and 40.0% for placebo (all active treatments higher than placebo, p < 0.001). Healing rates with Lansoprazole 30 mg were significantly higher than with Lansoprazole 15 mg at all time points (p < 0.05). Healing rates with omeprazole 20 mg were significantly higher than with Lansoprazole 15 mg at 4, 6, and 8 wk and were similar to those with Lansoprazole 30 mg. Based on patient diaries, Lansoprazole 30 mg produced better symptomatic relief than Lansoprazole 15 mg or omeprazole 20 mg, primarily early in the treatment course. Conclusions : Both Lansoprazole 30 mg and omeprazole 20 mg were more effective than Lansoprazole 15 mg in esophageal mucosal healing. Compared with omeprazole 20 mg, Lansoprazole 30 mg was as safe, was similarly effective with respect to esophageal healing, and provided superior symptomatic relief, primarily early in treatment. Lansoprazole 30 mg provided greater symptomatic relief than Lansoprazole 15 mg.
Marsha Raanan - One of the best experts on this subject based on the ideXlab platform.
-
multicenter double blind randomized placebo controlled trial assessing the efficacy and safety of proton pump inhibitor Lansoprazole in infants with symptoms of gastroesophageal reflux disease
The Journal of Pediatrics, 2009Co-Authors: Susan R Orenstein, Stuart Atkinson, Eric Hassall, Wanda Furmagajablonska, Marsha RaananAbstract:Objective To assess the efficacy and safety of Lansoprazole in treating infants with symptoms attributed to gastroesophageal reflux disease (GERD) that have persisted despite a ≥ 1-week course of nonpharmacologic management. Study design This multicenter, double-blind, parallel-group study randomized infants with persisting symptoms attributed to GERD to treatment with Lansoprazole or placebo for 4 weeks. Symptoms were tracked through daily diaries and weekly visits. Efficacy was defined primarily by a ≥ 50% reduction in measures of feeding-related crying and secondarily by changes in other symptoms and global assessments. Safety was assessed based on the occurrence of adverse events (AEs) and clinical/laboratory data. Results Of the 216 infants screened, 162 met the inclusion/exclusion criteria and were randomized. Of those, 44/81 infants (54%) in each group were responders—identical for Lansoprazole and placebo. No significant Lansoprazole–placebo differences were detected in any secondary measures or analyses of efficacy. During double-blind treatment, 62% of Lansoprazole-treated subjects experienced 1 or more treatment-emergent AEs, versus 46% of placebo recipients ( P = .058). Serious AEs (SAEs), particularly lower respiratory tract infections, occurred in 12 infants, significantly more frequently in the Lansoprazole group compared with the placebo group (10 vs 2; P = .032). Conclusions This study detected no difference in efficacy between Lansoprazole and placebo for symptoms attributed to GERD in infants age 1 to 12 months. SAEs, particularly lower respiratory tract infections, occurred more frequently with Lansoprazole than with placebo.
